Altman Peter 4

What Happened Peter Altman, President, CEO and a director of BioCardia, purchased 5,700 shares of BCDA in an open-market transaction on 2026-05-18. The filing reports a weighted-average price of $0.92 per share for a total cost of $5,244. The filing characterizes this as a purchase (code P), which is a direct buy of common stock.

Key Details

• Transaction date: 2026-05-18 (filed the same day)
• Shares acquired: 5,700; weighted-average price reported: $0.92; total value reported: $5,244
• Footnote: trades were executed in multiple lots at prices ranging from $0.89 to $1.02; the $0.92 figure is the weighted average (the filer offers to provide per-trade details on request)
• Shares owned after transaction: not specified in the provided filing
• Filing timeliness: filed on the same date as the reported transaction (no late filing flag)

Context Open-market purchases by executives are often watched by investors as a signal of confidence, but note this is a relatively small ($~5.2k) purchase in dollar terms. The multi-trade execution and disclosed price range mean the reported price is an average; specific lot-level details can be requested from the filer or SEC staff per the footnote.